The Anal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anal Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anal Cancer and features dormant and discontinued products.

GlobalData tracks 94 drugs in development for Anal Cancer by 70 companies/universities/institutes. The top development phase for Anal Cancer is phase ii with 43 drugs in that stage. The Anal Cancer pipeline has 93 drugs in development by companies and one by universities/ institutes. Some of the companies in the Anal Cancer pipeline products market are: TScan Therapeutics, F. Hoffmann-La Roche and AstraZeneca.

The key targets in the Anal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Human Papillomavirus Protein E7 (E7), and Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274).

The key mechanisms of action in the Anal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 11 drugs in Filing rejected/Withdrawn. The Anal Cancer pipeline products include 15 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Anal Cancer pipeline products market including Monoclonal Antibody, and Gene-Modified Cell Therapy.

Anal Cancer overview

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity.

For a complete picture of Anal Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.